Isaias Gendrano

Affiliations

Merck & Co, Rahway, NJ, USA.

Publications (1)

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.

The lancet. HIV

Avec: Jean-Michel Molina , Giuliano Rizzardini , Catherine Orrell , Alejandro Afani , Alexandra Calmy , Shinichi Oka , Federico Hinestrosa , Princy Kumar , Pablo Tebas , Sharon Walmsley , Anjana Grandhi , Stephanie Klopfer , Isaias Gendrano , Karen Eves , Todd A Correll , Michelle C Fox , Jason Kim

Réseau de co-auteurs

Jean-Michel Molina 1 collaboration

Giuliano Rizzardini 1 collaboration

Catherine Orrell 1 collaboration

Alejandro Afani 1 collaboration

Alexandra Calmy 1 collaboration

Shinichi Oka 1 collaboration

Federico Hinestrosa 1 collaboration

Princy Kumar 1 collaboration

Pablo Tebas 1 collaboration

Sharon Walmsley 1 collaboration

Anjana Grandhi 1 collaboration

Stephanie Klopfer 1 collaboration

Karen Eves 1 collaboration

Todd A Correll 1 collaboration

Michelle C Fox 1 collaboration

Jason Kim 1 collaboration